The Biggest Unsolved Problems in Sleep Medicine: What Science Still Can’t Explain

Sleep is a fundamental biological process, yet despite decades of research, many core questions about why we sleep, how sleep disorders develop, and the full impact of treatments like continuous positive airway pressure (CPAP) remain unanswered. Sleep medicine has made remarkable strides in diagnosing and managing conditions such as obstructive sleep apnea (OSA), but significant gaps in understanding persist. These unresolved issues not only challenge clinicians and researchers but also affect millions of people struggling with poor sleep and its wide-ranging health consequences.

This article explores the most pressing unsolved problems in sleep medicine today, drawing on the latest peer-reviewed research and clinical insights to clarify what we know, what we don’t, and why these mysteries matter for patient care and public health.

Why Do We Sleep? The Core Purpose Remains Elusive

One of the most fundamental questions in neuroscience and sleep medicine is: Why do we sleep? While theories abound — including memory consolidation, metabolic waste clearance, energy conservation, and synaptic homeostasis — no single explanation fully accounts for all observed functions of sleep across species.

The glymphatic system, discovered in 2012, revealed how cerebrospinal fluid flushes neurotoxic proteins like beta-amyloid during sleep, offering a compelling link between sleep and neurodegenerative disease prevention (Nature, 2013). Still, it remains unclear whether this is sleep’s primary evolutionary purpose or a beneficial side effect.

sleep needs vary widely among individuals and species — some animals function with minimal sleep, while others require up to 20 hours a day. This variability suggests that sleep may serve multiple, context-dependent functions rather than one universal role.

What Triggers the Transition Between Sleep and Wakefulness?

Although we understand much about the neurochemistry of sleep-wake regulation — involving neurotransmitters like adenosine, serotonin, norepinephrine, and orexin (hypocretin) — the exact mechanisms that trigger the initiation and termination of sleep states are still not fully mapped.

For instance, narcolepsy type 1 is strongly linked to the loss of orexin-producing neurons in the hypothalamus (Journal of Clinical Investigation, 2009), yet not all cases involve identifiable neuronal loss, and the autoimmune triggers remain poorly understood. Similarly, idiopathic hypersomnia — characterized by excessive daytime sleepiness without cataplexy or abnormal REM sleep — lacks clear biomarkers or consistent pathophysiological explanations.

These gaps hinder the development of targeted therapies and contribute to diagnostic delays, leaving many patients without effective treatment.

Why Does CPAP Therapy Fail in So Many Patients With Sleep Apnea?

Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate to severe obstructive sleep apnea, yet adherence rates remain disappointingly low. Studies reveal that anywhere from 30% to 50% of patients either refuse CPAP or discontinue use within the first year.

Common reasons include mask discomfort, nasal dryness, claustrophobia, and perceived lack of benefit — especially in patients with mild symptoms. However, even among those who use CPAP regularly, a significant subset experiences residual excessive daytime sleepiness despite normalized breathing during sleep.

This phenomenon, sometimes called “CPAP-resistant sleepiness,” suggests that OSA may involve more than just upper airway obstruction. Potential contributors include chronic sleep fragmentation, intermittent hypoxia-induced brain injury, autonomic dysregulation, or comorbid conditions like depression or insomnia (Sleep Medicine Reviews, 2017). Until we better understand these overlapping mechanisms, improving CPAP outcomes will remain challenging.

Can We Predict Who Will Develop Neurodegenerative Disease Based on Sleep Patterns?

Rapid eye movement (REM) sleep behavior disorder (RBD), in which individuals physically act out vivid dreams due to loss of muscle atonia, is one of the strongest known predictors of future neurodegenerative disease — particularly Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.

Studies show that over 80% of individuals with idiopathic RBD go on to develop a defined neurodegenerative syndrome within 10–15 years (Brain, 2017). Yet, we still cannot predict which individuals will progress, when symptoms will emerge, or how to intervene early to delay or prevent neurodegeneration.

Research into neuroinflammatory markers, alpha-synuclein seeding assays, and advanced neuroimaging is ongoing, but no proven disease-modifying therapies exist for those at high risk based on RBD alone.

Is There a “Best” Time to Sleep — And Does It Matter for Long-Term Health?

Circadian biology has shown that aligning sleep with the body’s internal clock improves metabolic health, cognitive performance, and mood regulation. Misalignment — as seen in shift perform, jet lag, or social jet lag — is linked to increased risks of obesity, diabetes, cardiovascular disease, and certain cancers (The Lancet, 2019).

However, individual circadian rhythms (chronotypes) vary significantly due to genetics, age, and lifestyle. While “night owls” and “early birds” both can achieve sufficient sleep duration, misalignment with societal schedules often leads to chronic sleep deprivation in evening-types.

What remains unclear is whether enforcing a uniform sleep schedule (e.g., 11 p.m. To 7 a.m.) is beneficial or harmful for those whose biology favors later timing. Personalized sleep medicine based on circadian phenotyping is an emerging frontier, but practical tools for widespread clinical use are still lacking.

Can Sleep Itself Be Used as a Therapeutic Tool?

Beyond treating sleep disorders, there is growing interest in harnessing sleep to improve overall health — for example, using targeted memory consolidation during sleep to treat PTSD or enhance learning.

Techniques like targeted memory reactivation (TMR), where cues associated with learning are replayed during slow-wave sleep, have shown promise in experimental settings (Nature Neuroscience, 2012). Similarly, transcranial slow-wave stimulation during sleep has been explored to boost memory in older adults and those with mild cognitive impairment.

Yet, translating these findings into safe, scalable, and effective clinical interventions remains a major hurdle. Questions about optimal timing, duration, individual variability, and long-term effects necessitate answers before sleep-based therapies can move beyond the lab.

Key Takeaways

• The fundamental purpose of sleep — while linked to brain detoxification, memory, and metabolism — is still not fully understood.
• Mechanisms governing sleep-wake transitions involve complex neurochemistry, but triggers for narcolepsy, idiopathic hypersomnia, and other central disorders remain unclear.
• CPAP adherence and effectiveness are limited by mask intolerance, residual symptoms, and incomplete understanding of OSA’s neurological impact.
• REM sleep behavior disorder is a powerful predictor of neurodegeneration, but we lack tools to prevent or delay disease onset in at-risk individuals.
• Circadian misalignment harms health, but personalized sleep timing based on chronotype is not yet standard in clinical practice.
• Sleep-based therapies (e.g., memory enhancement during sleep) show promise but require further validation before widespread use.

The Future of Sleep Medicine: Toward Personalized, Mechanism-Based Care

Solving these unsolved problems will require interdisciplinary collaboration between neuroscientists, pulmonologists, psychiatrists, geneticists, and data scientists. Advances in wearable technology, artificial intelligence for sleep staging, and multi-omics approaches are beginning to reveal subtypes of insomnia, sleep apnea, and circadian disorders that may respond differently to treatment.

As we move toward precision sleep medicine, the focus must shift from merely treating symptoms to understanding the underlying biological diversity of sleep disorders. Only then can we develop therapies that are not just effective, but truly transformative for the millions affected by poor sleep.

Until then, acknowledging what we don’t know is the first step toward asking better questions — and finding better answers.